These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 28919755)
41. Metformin as a new anti-cancer drug in adrenocortical carcinoma. Poli G; Cantini G; Armignacco R; Fucci R; Santi R; Canu L; Nesi G; Mannelli M; Luconi M Oncotarget; 2016 Aug; 7(31):49636-49648. PubMed ID: 27391065 [TBL] [Abstract][Full Text] [Related]
43. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702 [TBL] [Abstract][Full Text] [Related]
44. MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors. Pereira SS; Monteiro MP; Costa MM; Ferreira J; Alves MG; Oliveira PF; Jarak I; Pignatelli D J Cell Biochem; 2019 Jan; 120(1):894-906. PubMed ID: 30256438 [TBL] [Abstract][Full Text] [Related]
45. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. Hantel C; Lewrick F; Reincke M; Süss R; Beuschlein F J Endocrinol; 2012 May; 213(2):155-61. PubMed ID: 22407999 [TBL] [Abstract][Full Text] [Related]
46. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures Fragni M; Palma Lopez LP; Rossini E; Abate A; Cosentini D; Salvi V; Vezzoli S; Poliani PL; Bosisio D; Hantel C; Tiberio GAM; Grisanti S; Memo M; Terzolo M; Berruti A; Sigala S Mol Cell Endocrinol; 2019 Dec; 498():110585. PubMed ID: 31536779 [TBL] [Abstract][Full Text] [Related]
47. Antiandrogenic mechanisms of pesticides in human LNCaP prostate and H295R adrenocortical carcinoma cells. Robitaille CN; Rivest P; Sanderson JT Toxicol Sci; 2015 Jan; 143(1):126-35. PubMed ID: 25324206 [TBL] [Abstract][Full Text] [Related]
48. Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer. Rossini E; Tamburello M; Abate A; Beretta S; Fragni M; Cominelli M; Cosentini D; Hantel C; Bono F; Grisanti S; Poliani PL; Tiberio GAM; Memo M; Sigala S; Berruti A Front Endocrinol (Lausanne); 2021; 12():669426. PubMed ID: 33981288 [TBL] [Abstract][Full Text] [Related]
49. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma. Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247 [TBL] [Abstract][Full Text] [Related]
50. Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells. Martin G; Pilon A; Albert C; Vallé M; Hum DW; Fruchart JC; Najib J; Clavey V; Staels B Eur J Biochem; 1999 Apr; 261(2):481-91. PubMed ID: 10215860 [TBL] [Abstract][Full Text] [Related]
51. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910 [TBL] [Abstract][Full Text] [Related]
52. Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent. Pinto EM; Morton C; Rodriguez-Galindo C; McGregor L; Davidoff AM; Mercer K; Debelenko LV; Billups C; Ribeiro RC; Zambetti GP Clin Cancer Res; 2013 Apr; 19(7):1740-7. PubMed ID: 23406775 [TBL] [Abstract][Full Text] [Related]
53. Targeting estrogen receptor-α reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. Sirianni R; Zolea F; Chimento A; Ruggiero C; Cerquetti L; Fallo F; Pilon C; Arnaldi G; Carpinelli G; Stigliano A; Pezzi V J Clin Endocrinol Metab; 2012 Dec; 97(12):E2238-50. PubMed ID: 23074235 [TBL] [Abstract][Full Text] [Related]
54. Molecular markers and targeted therapies for adrenocortical carcinoma. Xu Y; Qi Y; Zhu Y; Ning G; Huang Y Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415 [TBL] [Abstract][Full Text] [Related]
55. A novel heat shock protein 90 inhibitor potently targets adrenocortical carcinoma tumor suppression. Wang T; Subramanian C; Blagg BSJ; Cohen MS Surgery; 2020 Jan; 167(1):233-240. PubMed ID: 31561992 [TBL] [Abstract][Full Text] [Related]
56. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy. Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317 [TBL] [Abstract][Full Text] [Related]
57. Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. Germano A; Rossin D; Leoni V; Iaia N; Saba L; Basile V; Puglisi S; Caccia C; Poli G; Biasi F; Terzolo M Cells; 2020 Apr; 9(4):. PubMed ID: 32260362 [TBL] [Abstract][Full Text] [Related]